{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:48:05Z","timestamp":1767829685860,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mechanisms for late-onset neutropenia (LON) after rituximab treatment are poorly defined both for non-Hodgkin lymphoma (NHL) and for autoimmune disorders. We performed a case\u2013control analysis of a prospective cohort of 169 evaluable consecutive rituximab-treated NHL patients to assess cytokines involved in neutro- and lymphopoiesis (G-CSF, SDF1, BAFF, APRIL) and inflammation (CRP) as possible LON mechanisms. Fifteen patients (9%) developed LON (peripheral blood \/PB\/ absolute neutrophil counts \/ANC\/\u2009&lt;\u20090.5 G\/L, all with marked depletion of CD20<jats:sup>+<\/jats:sup> B-lymphocytes in bone marrows); they were compared with 20 matched NHL controls without LON. At start of LON, significantly higher PB G-CSF and BAFF levels (<jats:italic>P<\/jats:italic>\u2009=\u20090.0004 and 0.006, respectively), as well as CRP rises were noted compared to controls; these G-CSF and BAFF and most CRP values returned to levels of the controls in post-LON samples. G-CSF (but not BAFF) changes correlated to CRP rises (but not to ANC levels). BAFF levels correlated significantly to absolute monocyte counts and PB large granular lymphocyte counts (but not to ANC, C-CSF or CRP values). No changes of SDF1 or APRIL levels were noted. Neither LON cases nor controls displayed anti-neutrophil autoantibodies. Collectively, LON in NHL patients was timewise related to transient bursts of blood G-CSF and BAFF concentrations, suggesting that these neutro- and lymphopoiesis growth factors play a role in emergence of rituximab-induced LON, and that inflammation may be a trigger for G-CSF production during LON.<\/jats:p>","DOI":"10.1007\/s12032-021-01516-8","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T10:03:02Z","timestamp":1621332182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas"],"prefix":"10.1007","volume":"38","author":[{"given":"Daniel","family":"Tesfa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitta","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henric","family":"Lindkvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3078-6131","authenticated-orcid":false,"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"H\u00e4gglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn E.","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Klimkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4014-2540","authenticated-orcid":false,"given":"Jan","family":"Palmblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","volume":"348","author":"E Voog","year":"2003","unstructured":"Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med. 2003;348:2691\u20134.","journal-title":"N Engl J Med"},{"key":"1516_CR2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/ehm.11.62","volume":"4","author":"D Tesfa","year":"2011","unstructured":"Tesfa D, Palmblad J. Late-onset neutropenia following rituximab treatment: incidence, clinical features and possible mechanisms. Expert Rev Hematol. 2011;4:619\u201325.","journal-title":"Expert Rev Hematol"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","volume":"19","author":"O Wolach","year":"2012","unstructured":"Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol. 2012;19:32\u20138.","journal-title":"Curr Opin Hematol"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1186\/ar2076","volume":"8","author":"T Vallerskog","year":"2006","unstructured":"Vallerskog T, Heimb\u00fcrger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:R167.","journal-title":"Arthritis Res Ther"},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","volume":"12","author":"MR Ehrenstein","year":"2016","unstructured":"Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367\u201372.","journal-title":"Nat Rev Rheumatol"},{"key":"1516_CR6","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1177\/0961203318777116","volume":"27","author":"I Parodis","year":"2018","unstructured":"Parodis I, S\u00f6der F, Faustini F, et al. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus\u2014distinct roles of BAFF and APRIL. Lupus. 2018;27:1470\u20138.","journal-title":"Lupus"},{"key":"1516_CR7","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1002\/jcp.28445","volume":"234","author":"AG Shabgah","year":"2019","unstructured":"Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. The role of BAFF and APRIL in rheumatoid arthritis. J Cell Physiol. 2019;234:17050\u201363.","journal-title":"J Cell Physiol"},{"key":"1516_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2007.11.009","volume":"116","author":"P Scapini","year":"2008","unstructured":"Scapini P, Bazzoni F, Cassatella MA. Regulation of B-cell-activating factor (BAFF)\/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol Lett. 2008;116:1\u20136.","journal-title":"Immunol Lett"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1084\/jem.20150577","volume":"213","author":"R Parsa","year":"2016","unstructured":"Parsa R, Lund H, Georgoudaki AM, et al. BAFF-secreting neutrophils drive plasma cell responses during emergency granulopoiesis. J Exp Med. 2016;213:1537\u201353.","journal-title":"J Exp Med"},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","volume":"9","author":"CR Smulski","year":"2018","unstructured":"Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival. Front Immunol. 2018;9:2285 (eCollection 2018).","journal-title":"Front Immunol"},{"key":"1516_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","volume":"106","author":"K Dunleavy","year":"2005","unstructured":"Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005;106:795\u2013802.","journal-title":"Blood"},{"key":"1516_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613\u201320.","journal-title":"Arthritis Rheum"},{"key":"1516_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/ajh.21818","volume":"85","author":"SC Li","year":"2010","unstructured":"Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia B-cell lymphoma correlates with Fc receptor Fc\u03b3RIIIa 158(V\/F) polymorphism. Am J Hematol. 2010;85:810\u20132.","journal-title":"Am J Hematol"},{"key":"1516_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13075-017-1241-0","volume":"19","author":"S Ajeganova","year":"2017","unstructured":"Ajeganova S, Tesfa D, H\u00e4gglund H, et al. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab. Arthritis Res Ther. 2017;19:44.","journal-title":"Arthritis Res Ther"},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.it.2017.01.004","volume":"38","author":"S Boettcher","year":"2017","unstructured":"Boettcher S, Manz MG. Regulation of inflammation- and infection-driven hematopoiesis. Trends Immunol. 2017;38:345\u201357.","journal-title":"Trends Immunol"},{"key":"1516_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaut.2018.10.016","volume":"95","author":"L Baert","year":"2018","unstructured":"Baert L, Manfroi B, Casez O, Sturm N, Huard B. The role of APRIL\u2014a proliferation inducing ligand\u2014in autoimmune diseases and expectations from its targeting. J Autoimmun. 2018;95:179\u201390.","journal-title":"J Autoimmun"},{"key":"1516_CR17","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.3324\/haematol.11031","volume":"92","author":"B Terrier","year":"2007","unstructured":"Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica. 2007;92:e20\u20133.","journal-title":"Haematologica"},{"key":"1516_CR18","volume-title":"Common toxicity criteria version 20 (CTC)","author":"Cancer Therapy Evaluation Program","year":"1999","unstructured":"Cancer Therapy Evaluation Program. Common toxicity criteria version 20 (CTC). Bethesda: National Institutes of Health, National Cancer Institute; 1999."},{"key":"1516_CR19","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/art.30427","volume":"63","author":"D Tesfa","year":"2011","unstructured":"Tesfa D, Ajeganova S, H\u00e4gglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209\u201314.","journal-title":"Arthritis Rheum"},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","volume":"129","author":"T Lamy","year":"2017","unstructured":"Lamy T, Moignet A, Loughran TP Jr. LGL leukemia: from pathogenesis to treatment. Blood. 2017;129:1082\u201394.","journal-title":"Blood"},{"key":"1516_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1586\/17474086.2016.1142867","volume":"9","author":"J Palmblad","year":"2016","unstructured":"Palmblad J, Nilsson CC, H\u00f6glund P, Papadaki HA. How we diagnose and treat neutropenia in adults. Expert Rev Hematol. 2016;9:479\u201387.","journal-title":"Expert Rev Hematol"},{"key":"1516_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1046\/j.1365-2141.1999.01390.x","volume":"105","author":"J Bux","year":"1999","unstructured":"Bux J, Hofmann C, Welte K. Serum G-CSF levels are not increased in patients with antibody-induced neutropenia unless they are suffering from infectious diseases. Br J Haematol. 1999;105:616\u20137.","journal-title":"Br J Haematol"},{"key":"1516_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","volume":"26","author":"T Papadaki","year":"2002","unstructured":"Papadaki T, Stamatopoulos K, Stavroyianni N, et al. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res. 2002;26:597\u2013600.","journal-title":"Leuk Res"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/sj.leu.2405077","volume":"22","author":"K Stamatopoulos","year":"2008","unstructured":"Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia. 2008;22:1446\u20139.","journal-title":"Leukemia"},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/ehm.11.12","volume":"4","author":"E Andr\u00e8s","year":"2011","unstructured":"Andr\u00e8s E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol. 2011;4:143\u201351.","journal-title":"Expert Rev Hematol"},{"key":"1516_CR26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","volume":"146","author":"F Andersohn","year":"2007","unstructured":"Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146:657\u201365.","journal-title":"Ann Intern Med"},{"key":"1516_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ajh.24479","volume":"91","author":"F Tricta","year":"2016","unstructured":"Tricta F, Uetrecht J, Galanello R, et al. Deferiprone-induced agranulocytosis: 20 years of clinical observations. Am J Hematol. 2016;91:1026\u201331.","journal-title":"Am J Hematol"},{"key":"1516_CR28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12032-008-9049-z","volume":"25","author":"D Tesfa","year":"2008","unstructured":"Tesfa D, Gelius T, Sander B, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol. 2008;25:374\u20139.","journal-title":"Med Oncol"},{"key":"1516_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1084\/jem.20111908","volume":"209","author":"BN Jaeger","year":"2012","unstructured":"Jaeger BN, Donadieu J, Cognet C, et al. Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. J Exp Med. 2012;209:565\u201380.","journal-title":"J Exp Med"},{"key":"1516_CR30","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1182\/blood-2015-02-629444","volume":"125","author":"RB Day","year":"2015","unstructured":"Day RB, Bhattacharya D, Nagasawa T, Link DC. Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice. Blood. 2015;125:3114\u20137.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01516-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01516-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01516-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T10:21:43Z","timestamp":1622110903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01516-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01516-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DT is currently employed by Swedish Orphan Biovitrum AB, SE-112 76 Stockholm, Sweden. At the time of the study: no other conflicts of interest have been declared. All other authors: no conflict of interest are reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved of the Ethics Committee of the Karolinska Institutet.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave written consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"70"}}